BIT:1SAN • FR0000120578
The current stock price of 1SAN.MI is 82.18 EUR. In the past month the price decreased by -0.15%. In the past year, price decreased by -16.53%.
ChartMill assigns a fundamental rating of 5 / 10 to 1SAN.MI. There are concerns on the financial health of 1SAN.MI while its profitability can be described as average.
Over the last trailing twelve months 1SAN.MI reported a non-GAAP Earnings per Share(EPS) of 7.82. The EPS increased by 1.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
30 analysts have analysed 1SAN.MI and the average price target is 98.32 EUR. This implies a price increase of 19.64% is expected in the next year compared to the current price of 82.18.
For the next year, analysts expect an EPS growth of 8.1% and a revenue growth 6.17% for 1SAN.MI
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.72 | 198.536B | ||
| SNW | SANOFI | 9.72 | 198.464B | ||
| MRK | MERCK KGAA | 14.64 | 55.543B | ||
| UNC | UCB SA | 26.34 | 52.693B | ||
| UCB | UCB SA | 24.53 | 49.075B | ||
| 1BAYN | BAYER AG-REG | 8.6 | 41.291B | ||
| BAYN | BAYER AG-REG | 8.6 | 41.272B | ||
| IPN | IPSEN | 14.47 | 13.837B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.69 | 10.126B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 84587
Phone: 33153774000
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
The current stock price of 1SAN.MI is 82.18 EUR. The price increased by 1.92% in the last trading session.
SANOFI (1SAN.MI) has a dividend yield of 3.8%. The yearly dividend amount is currently 3.79.
1SAN.MI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for SANOFI (1SAN.MI) is 10.51. This is based on the reported non-GAAP earnings per share of 7.82 and the current share price of 82.18 EUR.
SANOFI (1SAN.MI) will report earnings on 2026-04-23.